Medicamen Biotech is a pharmaceutical company that was pulled from near-collapse and rebuilt into a factory for the world’s medicine cabinets. After a debt-ridden past, a new leadership team took charge in 2016 and methodically upgraded its plants to meet the standards of the most demanding regulators - first the WHO, then the EU, and finally the US FDA - so that the pills, syrups, and injections made inside could travel from Rajasthan and Uttarakhand to patients in over 35 countries. The recurring approach is to turn a manufacturing asset into a passport: get a plant certified by a rich-country regulator, then fill it with orders from both the company’s own brands and the contract manufacturing deals of other pharma companies who need a compliant factory. # Business segments A single engine at different stages of its global journey - a generics factory that makes tablets, capsules, liquids, and injectables, then sells them through three distinct channels: branded prescriptions in Indian cities, bulk shipments to distributors across Africa and Asia, and contract manufacturing for Western pharma companies that want a US FDA-approved plant without building one themselves. ## 1. The factory floor: making the medicine that the world buys **Three plants, each with a different regulatory badge, turn raw chemicals into finished pills, syrups, and cancer injections - and the badges determine which customers can buy from them.** - **The flagship plant is a six-block campus** - the 210,000 sq. ft. Bhiwadi facility houses separate production lines for penicillin-based drugs, non-penicillin tablets and capsules, liquid syrups, and a dedicated block for iron and folic acid supplements, so cross-contamination risk is physically eliminated by design. It holds WHO GMP certification, has been audited by Brazil’s ANVISA, and underwent an EU GMP inspection by Greek authorities that closed with observations, with final approval expected after submission of a formal response, which means its output is legal to sell across Europe, Africa, and Latin America. - **The oncology plant was built for the hardest test** - a 35,000 sq. ft. facility at Haridwar, built with an investment of ₹75 crore, makes cancer therapies in injectable and pill form, with an isolator-contained production line from Glatt that keeps operators safe and the product sterile. It can produce 2 to 2.5 million lyophilized (freeze-dried) vials and 140 million tablets a year, and in 2024 it passed a US FDA inspection, clearing the way for American sales. - **A smaller sister plant fills the gaps** - the 32,000 sq. ft. Haridwar Unit I handles general tablets, capsules, ointments, and oral liquids under WHO GMP certification, giving the company overflow capacity and a lower-cost site for products destined for emerging markets. - **Upgrades are continuous, not one-off** - the company has invested ₹45 crore from its own cash flows over recent years to modernise oral solid and liquid blocks, expand quality-control labs, and bring Haridwar Unit I to WHO GMP standards, because each new regulatory approval unlocks a fresh set of buyers. ## 2. The branded-generics channel: selling under its own name in India and beyond **The company puts its own label on the medicine and sells it through a network of marketing representatives to doctors, hospitals, and pharmacies - a higher-margin game than contract manufacturing, but one that requires a sales force on the ground.** - **A domestic subsidiary was built from scratch** - Medicamen Life Sciences, incorporated in 2022 and majority-owned by the company, deploys a 108-member marketing team across nine states in Northern and Western India, carrying a portfolio of 74 products for heart disease, diabetes, and pain management into 16 cities. The subsidiary’s minority partners are two industry veterans with decades of pharma marketing and distribution experience, so the company bought local knowledge rather than learning it the hard way. - **Oncology gets its own dedicated sales force** - under the brand Vivo Oncology, a separate team of 30 senior marketing personnel operates from 17 headquarters across India, supplying cancer drugs to institutions like Tata Memorial, AIIMS, and Fortis. Twelve oncology products with 53 SKUs are already on the market, and 25 more are in the pipeline. - **The European shelf is being stocked product by product** - the company received EU approval for its Paracetamol registration from Denmark’s medicine authority in early 2026, and has signed a distribution deal with XGX Pharma for an Amoxicillin dispersible tablet, with seven more products under development for EU filing. ## 3. The export-generics channel: Africa’s pharmacy, plus a long tail of countries **Roughly 80% of the company’s sales come from outside India, with Africa alone accounting for about 70% - a business built on registering products in dozens of countries and shipping them to local distributors who handle the last mile.** - **The country list reads like an atlas** - products move to Brazil, Cuba, the Dominican Republic, Afghanistan, Cambodia, Myanmar, Nepal, Kyrgyzstan, Cameroon, Congo, Ivory Coast, Kenya, Nigeria, Zambia, and Zimbabwe, among others, through wholesale drug distributors and stockists who buy in bulk. - **Regulated markets are the next frontier** - the company has submitted documents for plant approval in Australia (where its subsidiary Opal Pharmaceuticals already holds 14 products), filed for plant approval in Canada, commenced dossier filings in Vietnam, and signed an agreement with a South African business group to enter that country’s $4 billion pharmaceutical market. ## 4. The CDMO channel: renting the factory to other pharma companies **Western pharma firms pay Medicamen to develop and manufacture products for them, using the company’s regulatory approvals as a shortcut - the customer owns the marketing authorisation, but Medicamen owns the production line.** - **Three US contracts are already signed** - the company has secured CDMO agreements with three US-based partners, and in early 2025 it locked in a 10-year manufacturing and supply deal with a leading pharma distributor covering the US and Europe, which will fill the US FDA-approved oncology plant with contracted orders. - **European customers are joining the roster** - XGX Pharma of Denmark signed a CDMO contract for six products that Medicamen will develop and manufacture, while Vital Pharma Nordic, also of Denmark, has a separate multi-product CDMO agreement. In each case, the customer holds the market authorisation, so Medicamen earns a manufacturing margin without bearing the commercial risk of selling the product. - **The factory’s capacity is the offer** - the company explicitly markets its technical, intermediate, API, and dosage-form capacity for both its own consumption and contract manufacturing services, meaning the same machines that make Medicamen’s own brands can be booked by an outside customer. # Research and development **A 75-scientist team inside the Bhiwadi plant invents the formulations, proves they are equivalent to the originator’s drug, and prepares the regulatory dossiers that unlock every new market - without this engine, the factory has nothing new to sell.** - **The lab is government-recognised** - the R&D centre is approved by India’s Department of Scientific and Industrial Research and houses three wings covering chemical research, analytical research, and formulation development for both oncology and non-oncology products. - **It can challenge patents** - the team has Para IV filing capability, meaning it can develop versions of patented drugs using different polymorphs (crystal structures) of the active ingredient and file for approval before the patent expires, a capability few Indian generic firms possess. - **The first US ANDA was an in-house job** - the active pharmaceutical ingredient for Bortezomib injection, the company’s first US FDA-approved generic, was developed by its own R&D team and manufactured at parent company Shivalik Rasayan, proving the lab can take a molecule from concept to a regulated-market approval. - **The pipeline is the future inventory** - the team has developed 15 molecules, filed 15 patents, and is working on 10 non-oncology products for the EU, alongside products targeting antimicrobial resistance and targeted-delivery cancer drugs. # Group structure and partners **The company sits inside a parent group that supplies its raw materials, and it has built a web of subsidiaries and alliance partners that act as its sales force in markets where it has no boots on the ground.** - **The parent is also the API supplier** - Shivalik Rasayan Limited owns about 43% of Medicamen Biotech and operates a US FDA-approved active pharmaceutical ingredient plant, giving Medicamen a captive source of the chemical core of its finished drugs. The same chairman, Rahul Bishnoi, leads both companies. - **Two subsidiaries extend the reach** - Opal Pharmaceuticals in Australia, acquired in 2019, holds 14 product registrations and serves as the company’s beachhead in a regulated Asia-Pacific market. Medicamen Life Sciences, the domestic branded business, is 60% owned and run with two industry veterans as minority partners. - **Partners are the distribution network** - XGX Pharma and Vital Pharma Nordic cover Denmark and the broader European market; a South African conglomerate is handling registration and marketing in that country; a Canadian partner covers supply and marketing of products; and three US-based CDMO customers book manufacturing capacity.